These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 8827950)
1. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Ernsberger P; Koletsky RJ; Collins LA; Bedol D Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():275-82. PubMed ID: 8827950 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764 [TBL] [Abstract][Full Text] [Related]
3. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453 [TBL] [Abstract][Full Text] [Related]
4. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X. Ernsberger P; Koletsky RJ; Friedman JE Ann N Y Acad Sci; 1999 Nov; 892():272-88. PubMed ID: 10842668 [TBL] [Abstract][Full Text] [Related]
5. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. Ernsberger P; Friedman JE; Koletsky RJ J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981 [TBL] [Abstract][Full Text] [Related]
6. Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study. Mikulášková B; Holubová M; Pražienková V; Zemenová J; Hrubá L; Haluzík M; Železná B; Kuneš J; Maletínská L Nutr Diabetes; 2018 Jan; 8(1):5. PubMed ID: 29339795 [TBL] [Abstract][Full Text] [Related]
7. Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats. Mervaala EM; Malmberg L; Teräväinen TL; Lähteenmäki T; Karjala K; Paakkari I; Pörsti I; Mest HJ; Vapaatalo H; Karppanen H Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):107-14. PubMed ID: 9228197 [TBL] [Abstract][Full Text] [Related]
8. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Friedman JE; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Kaung HL; Ernsberger P Am J Physiol; 1997 Nov; 273(5):E1014-23. PubMed ID: 9374689 [TBL] [Abstract][Full Text] [Related]
9. Cardiac effects of moxonidine in spontaneously hypertensive obese rats. Mukaddam-Daher S; Menaouar A; El-Ayoubi R; Gutkowska J; Jankowski M; Velliquette RA; Ernsberger P Ann N Y Acad Sci; 2003 Dec; 1009():244-50. PubMed ID: 15028594 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894 [TBL] [Abstract][Full Text] [Related]
11. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. Sun Z; Ernsberger P J Pharmacol Exp Ther; 2007 Feb; 320(2):845-52. PubMed ID: 17095615 [TBL] [Abstract][Full Text] [Related]
13. Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats. Wyss JM; Mozaffari MS; Roysommuti S J Hypertens; 1995 Sep; 13(9):1037-42. PubMed ID: 8586822 [TBL] [Abstract][Full Text] [Related]
14. Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats. Carlson SH; Shelton J; White CR; Wyss JM Hypertension; 2000 Jan; 35(1 Pt 2):403-8. PubMed ID: 10642332 [TBL] [Abstract][Full Text] [Related]
15. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. Prichard BN; Owens CW; Graham BR J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737 [TBL] [Abstract][Full Text] [Related]
16. Acceleration of renal disease in obese SHR by exacerbation of hypertension. Koletsky RJ; Boccia J; Ernsberger P Clin Exp Pharmacol Physiol Suppl; 1995 Dec; 22(1):S254-6. PubMed ID: 9072379 [TBL] [Abstract][Full Text] [Related]
17. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. Velliquette RA; Ernsberger P J Pharmacol Exp Ther; 2003 Aug; 306(2):646-57. PubMed ID: 12756274 [TBL] [Abstract][Full Text] [Related]
18. Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome. Selejan SR; Linz D; Tatu AM; Hohl M; Speer T; Ewen S; Mahfoud F; Kindermann I; Zamyatkin O; Kazakov A; Laufs U; Böhm M J Mol Cell Cardiol; 2018 Sep; 122():34-46. PubMed ID: 30096408 [TBL] [Abstract][Full Text] [Related]
19. The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. Bing C; King P; Pickavance L; Brown M; Ziegler D; Kaan E; Williams G Br J Pharmacol; 1999 May; 127(1):35-42. PubMed ID: 10369453 [TBL] [Abstract][Full Text] [Related]
20. Involvement of the sympathetic nervous system in antihypertensive effect of cicletanine in salt-loaded young spontaneously hypertensive rats. Ando K; Ono A; Sato Y; Asano S; Fujita T Am J Hypertens; 1994 Jun; 7(6):550-4. PubMed ID: 7917154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]